A Phase 4 interventional study of Tenecteplase and PCI in Myocardial Infarction, sponsored by Boehringer Ingelheim. Terminated at 177 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-29.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Myocardial Infarction by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Myocardial Infarction · Boehringer Ingelheim.
Among the 12 studies in Myocardial Infarction by Boehringer Ingelheim, this one is one of 2 that started in 2003, is the only one in phase 4, and was the 2nd registered.
2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.
Browse Myocardial Infarction studies →None of the 12 studies in Myocardial Infarction by Boehringer Ingelheim is open now. The open studies under Myocardial Infarction, anywhere →
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,671 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 1,639 across the 8 interventional studies, 206 across the 4 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Myocardial Infarction by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.
Inclusion Criteria:
(Otherwise the patients fulfill the usual selection criteria for thrombolytic treatment and PCI)
Exclusion Criteria: None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Death or cardiogenic shock or congestive heart failure within 90 days
Time frame: 90 days
Death or cardiogenic shock or congestive heart failure within 30 days
Time frame: 30 days
Cardiogenic shock or congestive heart failure within 90 days
Time frame: 90 days
Death
Time frame: 90 days
Cardiogenic shock
Time frame: 90 days
Reinfarction
Time frame: 90 days
Repeat target vessel revascularisation (TVR)
Time frame: 90 days
Rehospitalisation for congestive heart failure
Time frame: 90 days
Rehospitalisation for cardiogenic shock
Time frame: 90 days
Rehospitalisation for other cardiac reasons
Time frame: 90 days
Congestive heart failure
Time frame: 90 days
N-terminal pro-brain natriuretic peptide (NT pro-BNP)
Time frame: 90 days
Disabling stroke
Time frame: 90 days
Total stroke
Time frame: 90 days
Rehospitalisation for stroke or ICH (intrancranial haemorrhage)
Time frame: 90 days
Showing the first 100 of 177 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2003 and a primary completion of Jul 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase